Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations (2016 - 2025)

Syndax Pharmaceuticals has reported Cash from Operations over the past 11 years, most recently at 69488000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 69488000.0 for Q4 2025, down 21.08% from a year ago — trailing twelve months through Dec 2025 was 322980000.0 (down 17.49% YoY), and the annual figure for FY2025 was 322980000.0, down 17.49%.
  • Cash from Operations for Q4 2025 was 69488000.0 at Syndax Pharmaceuticals, up from 70535000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for SNDX hit a ceiling of 100709000.0 in Q4 2021 and a floor of 95162000.0 in Q1 2025.
  • Median Cash from Operations over the past 5 years was 41640000.0 (2022), compared with a mean of 43151400.0.
  • Biggest five-year swings in Cash from Operations: surged 744.29% in 2021 and later tumbled 122.73% in 2022.
  • Syndax Pharmaceuticals' Cash from Operations stood at 100709000.0 in 2021, then tumbled by 122.73% to 22894000.0 in 2022, then plummeted by 80.61% to 41349000.0 in 2023, then crashed by 38.79% to 57388000.0 in 2024, then fell by 21.08% to 69488000.0 in 2025.
  • The last three reported values for Cash from Operations were 69488000.0 (Q4 2025), 70535000.0 (Q3 2025), and 87795000.0 (Q2 2025) per Business Quant data.